OpenLB
Open Library of Bioscience
Advanced Search
Kidney360
02 01, 2023;4 (2): 217-225.

Prediagnostic Appearance of Thrombospondin Type-1 Domain 7A Autoantibodies in Membranous Nephropathy.

Peter D Burbelo, Stephen W Olson, Jason M Keller, Megha Joshi, Daniella M Schwartz, Yung-Jen Chuang, Gérard Lambeau, Laurence H Beck, Meryl Waldman
Author Information
  1. Peter D Burbelo: National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
  2. Stephen W Olson: Nephrology Department, Walter Reed National Military Medical Center, Bethesda, Maryland.
  3. Jason M Keller: National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
  4. Megha Joshi: Nephrology Department, Walter Reed National Military Medical Center, Bethesda, Maryland.
  5. Daniella M Schwartz: Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  6. Yung-Jen Chuang: School of Medicine, National Tsing Hua University, Hsinchu, Taiwan, Republic of China.
  7. Gérard Lambeau: Université Côte d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne Sophia Antipolis, France.
  8. Laurence H Beck: Department of Medicine, Section of Nephrology, Boston University School of Medicine, Boston, Massachusetts.
  9. Meryl Waldman: Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
PMID: 36821613 DOI: 10.34067/KID.0005112022

Abstract

No abstract text available.

Associated Data

ClinicalTrials.gov | NCT00977977

References

Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. doi: 10.2215/CJN.11761116 [DOI: 10.2215/CJN.11761116]
Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56(1):157-167. doi: 10.1053/j.ajkd.2010.01.008 [DOI: 10.1053/j.ajkd.2010.01.008]
Ronco P, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens. Curr Opin Nephrol Hypertens. 2021;30(3):287-293. doi: 10.1097/MNH.0000000000000697 [DOI: 10.1097/MNH.0000000000000697]
Beck LH Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457 [DOI: 10.1056/NEJMoa0810457]
Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287. doi: 10.1056/NEJMoa1409354 [DOI: 10.1056/NEJMoa1409354]
Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-679. doi: 10.1016/j.kint.2018.10.024 [DOI: 10.1016/j.kint.2018.10.024]
Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-313. doi: 10.1080/0886022X.2018.1456457 [DOI: 10.1080/0886022X.2018.1456457]
De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421-430. doi: 10.1681/ASN.2016070776 [DOI: 10.1681/ASN.2016070776]
Reinhard L, Thomas C, Machalitza M, et al. Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy. Sci Rep. 2021;11(1):16188. doi: 10.1038/s41598-021-94921-y [DOI: 10.1038/s41598-021-94921-y]
Hoxha E, Beck LH Jr., Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520-531. doi: 10.1681/ASN.2016010050 [DOI: 10.1681/ASN.2016010050]
Burbelo PD, Beck LH Jr., Waldman M. Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy. J Immunol Methods. 2017;444:17-23. doi: 10.1016/j.jim.2017.02.001 [DOI: 10.1016/j.jim.2017.02.001]
Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol. 2020;31(1):208-217. doi: 10.1681/ASN.2019050538 [DOI: 10.1681/ASN.2019050538]
Wang CH, Su PT, Du XY, et al. Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation. J Cell Physiol. 2010;222(3):685-694. doi: 10.1002/jcp.21990 [DOI: 10.1002/jcp.21990]
Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J Vis Exp. 2009;32:1549. doi: 10.3791/1549 [DOI: 10.3791/1549]
Ching KH, Burbelo PD, Tipton C, et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One. 2012;7(2):e32001. doi: 10.1371/journal.pone.0032001 [DOI: 10.1371/journal.pone.0032001]
Seifert L, Hoxha E, Eichhoff AM, et al . The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy. J Am Soc Nephrol. 2018;29(5):1536-1548. doi: 10.1681/ASN.2017070805 [DOI: 10.1681/ASN.2017070805]
Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642-1651. doi: 10.2215/CJN.01460217 [DOI: 10.2215/CJN.01460217]
Zhang D, Zou J, Zhang C, Zhang W, Lin F, Jiang G. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China. Med Sci Monit. 2018;24:5076-5083. doi: 10.12659/MSM.909815 [DOI: 10.12659/MSM.909815]
Hanset N, Aydin S, Demoulin N, et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis. 2020;76(5):624-635. doi: 10.1053/j.ajkd.2020.04.013 [DOI: 10.1053/j.ajkd.2020.04.013]
Matsumoto A, Matsui I, Namba T, et al. VEGF-A links angiolymphoid hyperplasia with eosinophilia (ALHE) to THSD7A membranous nephropathy: a report of 2 cases. Am J Kidney Dis. 2019;73(6):880-885. doi: 10.1053/j.ajkd.2018.10.009 [DOI: 10.1053/j.ajkd.2018.10.009]
Chen M, Zhang L, Zhong W, Zheng K, Ye W, Wang M. Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient. Front Immunol. 2021;12:619147. doi: 10.3389/fimmu.2021.619147 [DOI: 10.3389/fimmu.2021.619147]
Schwartz DM, Blackstone SA, Sampaio-Moura N, et al. Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20. Ann Rheum Dis. 2020;79(3):429-431. doi: 10.1136/annrheumdis-2019-215918 . [DOI: 10.1136/annrheumdis-2019-215918]
Aeschlimann FA, Batu ED, Canna SW, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77(5):728-735. doi: 10.1136/annrheumdis-2017-212403 [DOI: 10.1056/NEJMoa0810457]
Ge YC, Jin B, Zeng CH, et al. PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy. BMC Nephrol. 2016;17(1):185. doi: 10.1186/s12882-016-0407-3 [DOI: 10.1186/s12882-016-0407-3]
Iwakura T, Fujigaki Y, Katahashi N, et al. Membranous nephropathy with an enhanced granular expression of thrombospondin type-1 domain-containing 7A in a pregnant woman. Intern Med. 2016;55(18):2663-2668. doi: 10.2169/internalmedicine.55.6726 [DOI: 10.2169/internalmedicine.55.6726]
Caza TN, Hassen SI, Kenan DJ, et al. Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy. Kidney360. 2021;2(8):1275-1286. doi: 10.34067/KID.0001492021 [DOI: 10.34067/KID.0001492021]
Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. 2021;100(1):171-181. doi: 10.1016/j.kint.2020.09.016 [DOI: 10.1016/j.kint.2020.09.016]
Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol. 2021;32(3):695-706. doi: 10.1681/ASN.2020081181 [DOI: 10.1681/ASN.2020081181]

Grants

  1. Z99 DA999999/NIDA NIH HHS

MeSH Term

Humans
Glomerulonephritis, Membranous
Thrombospondins
Autoantibodies

Chemicals

Thrombospondins
Autoantibodies
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural

Word Cloud

Similar Articles

Cited By